Electra Therapeutics Inc. (ETRA) Stock Price & Analysis

10 Followers

ETRA Stock Chart & Stats

$9.45$1.46(18.27%)

At close: Nov 11 4:00 PM EST

Day’s Range: $8.18 - $9.49
52-Week Range: $6.87 - $15.50
Previous Close: $7.99
Volume: N/A
Average Volume (3M): 423.63K
Market Cap: $501.51M
Enterprise Value: N/A
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: -2.61
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Electra Therapeutics Inc. News

Electra Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Electra Therapeutics (ETRA) with a Buy rating and $30 price target Electra is a late clinical-stage biopharmaceutical company focused on pioneering a

2w agoETRA

Electra Therapeutics initiated with an Overweight at JPMorgan

JPMorgan analyst Anupam Rama initiated coverage of Electra Therapeutics (ETRA) with an Overweight rating and $36 price target The firm says the company’s ipsoprubart, currently in a Phase 2/3 pivotal

3w agoETRA

Electra Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Electra Therapeutics (ETRA) with an Overweight rating. Electra is pioneering a novel immunology approach with ipsoprubart, a pan-SIRP-targeting immune cell depleter in Phase 3 for

1M agoETRA

Electra Therapeutics initiated with a Buy at Jefferies

Jefferies initiated coverage of Electra Therapeutics (ETRA) with a Buy rating and $32 price target Electra is a clinical-stage biotech developing SIRP-directed therapies, with lead asset ipsoprubart being studied for

1M agoETRA

Electra Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Eric Schmidt initiated coverage of Electra Therapeutics (ETRA) with an Overweight rating. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

1M agoETRA

Electra Therapeutics initiated with an Outperform at Evercore ISI

Evercore ISI initiated coverage of Electra Therapeutics (ETRA) with an Outperform rating and $36 price target Lead asset ipsoprubart showed a 100% eight-week survival signal in a disease where the

1M agoETRA

Electra Therapeutics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Electra Therapeutics (ETRA) with a Buy rating and no price target The firm believes ipsoprubart has the potential to transform secondary hemophagocytic lymphohistiocytosis into a

1M agoETRA

Electra Therapeutics Completes IPO and Updates Governance

Electra Therapeutics Inc. ( ($ETRA) ) just unveiled an update. On September 21, 2026, Electra Therapeutics, Inc. closed its initial public offering of 23,333,334 shares of common stock at a

1M ago8K ETRA

Opening Day: Electra Therapeutics, Orion180 make market debuts

Nscale Limited has filed for an IPO and aims to list on the New York Stock Exchange, as Electra Therapeutics and Orion180 Insurance made their market debuts after pricing their

1M agoECR LZO

Electra Therapeutics opens at $15, IPO priced at $15 per share

Electra Therapeutics (ETRA), a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, priced its upsized initial public

1M agoETRA

Electra Therapeutics indicated to open at $20, IPO priced at $15

1M agoETRA

ETRA FAQ

What was Electra Therapeutics Inc.’s price range in the past 12 months?

Electra Therapeutics Inc. lowest stock price was $6.87 and its highest was $15.50 in the past 12 months.

What is Electra Therapeutics Inc.’s market cap?

Electra Therapeutics Inc.’s market cap is $501.51M.

When is Electra Therapeutics Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is Electra Therapeutics Inc. overvalued?

According to Wall Street analysts Electra Therapeutics Inc.’s price is currently Undervalued.

Does Electra Therapeutics Inc. pay dividends?

Electra Therapeutics Inc. does not currently pay dividends.

What is Electra Therapeutics Inc.’s EPS estimate?

Electra Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Electra Therapeutics Inc. have?

Electra Therapeutics Inc. has 62,766,956 shares outstanding.

Which hedge fund is a major shareholder of Electra Therapeutics Inc.?

Currently, no hedge funds are holding shares in ETRA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Electra Therapeutics Inc. Stock Smart Score

Outperform

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description